Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 129 participants.
Also called NCT05612035
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 129 participants
- Sponsor
- Registry
-
NCT05612035 -
2022-501201-13-00 -
U1111-1279-8512
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Colombia, France, Germany, Guatemala, Israel, Italy, Mexico, Peru, South Africa, South Korea, Spain, Switzerland, Türkiye, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05612035. Randomized; triple masking; primary purpose treatment. Start 2023-03-16 (actual); primary completion 2026-04-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
- Condition
- Pulmonary Hypertension
- Condition
- Chronic Obstructive Pulmonary Disease
- Intervention (Drug)
- Frespaciguat
- Intervention (Drug)
- Placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct05612035- Content hash
4fd35fdfe062b980672977aaa855570255f812f91280c0a00f4ed85dfbdf98ca